Why pharma device lifecycle programmes need stronger governance

In short

Pharma device lifecycle programmes need stronger governance because global consistency, audit evidence, controlled change, asset records and secure retirement matter across sites and countries. The issue is not only device supply; it is proving that the lifecycle process stays controlled.

Why this industry is different

Pharma environments put a high premium on governance, evidence and controlled execution. Device lifecycle decisions need clear ownership, change discipline, asset records and secure retirement evidence across countries and sites.

Lifecycle risks to control

• Governance.
• Audit Evidence.
• Controlled Change.
• Asset Records.
• Secure Retirement.

Where the model breaks down

The model usually breaks down at the handoffs between suppliers, systems and countries. One party may know what was ordered, another may know what shipped, another may know what was assigned and another may know what was recovered.

If those records do not connect, enterprise teams spend time reconciling data instead of improving the lifecycle. That creates slower decisions, weaker proof, more local variation and less confidence in the operating model.

How Egiss frames it

Egiss frames this as an operating-model issue. The objective is one global standard with local execution, supported by lifecycle services, governance and the Blue Stripe Guarantee. The strategy proof set includes delivery to 180+ countries, 1.6 million end-users on contract, 98% on-time delivery, +79 NPS, EcoVadis Gold, ISO certifications, R2v3, named customer references and partner authorisations, subject to final approved public wording and scope.

Buyer questions

• How will governance be governed across countries?
• How will audit evidence be governed across countries?
• How will controlled change be governed across countries?
• How will asset records be governed across countries?
• How will secure retirement be governed across countries?
• Which evidence proves the model is working?
• Which team owns exceptions when the process crosses countries or suppliers?

Next step

Use this topic to test whether the current model is a set of local processes or a governed lifecycle. If the answer differs by country, supplier or system, the next step is to review the operating model before the next refresh, renewal or RFP.

FAQ

What makes pharma IT lifecycle management complex?

Pharma device lifecycle programmes need stronger governance because global consistency, audit evidence, controlled change, asset records and secure retirement matter across sites and countries. The issue is not only device supply; it is proving that the lifecycle process stays controlled.

Why does this matter for global enterprises?

It matters because multinational organisations need technology decisions to remain controlled across countries, systems and lifecycle stages. A local fix can solve a short-term problem while creating later cost, risk, support friction or reporting gaps.

What should buyers ask suppliers?

Buyers should ask how the supplier handles country scope, local execution, systems integration, asset data, delivery measurement, exception governance, ITAD, sustainability reporting and contractual accountability.

How can Egiss help?

Egiss helps connect hardware access, services, governance and the Blue Stripe Guarantee into one global technology lifecycle model. The model is designed to support local execution while giving enterprise teams clearer visibility, control and accountability.